Kornimate/medical-research-clean huggingface dataset:
pain inhibition in patients with rheumatoid arthritis and central sensitivity syndromes

Conditions: Fatigue Syndrome, Chronic; Fibromyalgia; Arthritis, Rheumatoid

Summary: both patients with peripheral structural pathologies, like rheumatoid arthritis (ra)-patients, or patients with central sensitivity syndromes (css) suffer chronic pain. css are characterized by an increased responsiveness of central pain neurons. an impaired endogenous pain inhibition is already demonstrated in css. in the present study the investigators want to evaluate the efficacy of pain inhibition in response to physical stressors and whether the efficacy is opioid-mediated in two chronic pain populations (ra \& ccs) compared to controls. therefore a triple-blinded randomized controlled trial (rct) with cross-over design will be performed. the efficacy of wind-up of pain and spatial summation of pain is evaluated before and after a submaximal exercise, while the experimental group receives a selective serotonin reuptake inhibitor. participants are 20 ra-patients and 20 css-patients, more specific patients with fibromyalgia and chronic fatigue syndrome, and 30 healthy controls. this way, the investigators analyze how pain inhibition reacts on different types of physical stressors in different pain patients and if pain inhibition is opioid-mediated.


Eligibility criteria:
inclusion criteria: * each study participant should be aged between 18 and 65 years. all three groups will be comparable for age, gender, education level and socioeconomic status; both patient groups will be comparable for illness duration. * the central sensitivity syndrome (css) group will comply with the diagnostic criteria for fibromyalgia (fm) as defined by the american college of rheumatology and the centre of disease control criteria for chronic fatigue syndrome (cfs). * at the time of study participation, healthy control subjects cannot suffer any pain complaints. sedentary is defined as a sedentary job and \< 3 h moderate physical activity/week. moderate physical activity is defined as activity demanding at least the threefold of the energy spent passively. * patients have to be able to cycle on a bicycle ergometer. exclusion criteria: * in order to preclude confounding factors, participants cannot be pregnant (pregnancy test) or until 1 year postnatal and will be asked to stop medication two weeks prior to study participation, not to undertake physical exertion, and to refrain from consuming caffeine, alcohol or nicotine on the day of the experiment. for ethical reasons, rheumatoid arthritis(ra)-patients are able to take non-opioid pain medication as described in the 1st step of the world health organization analgesic ladder (non-steroidal anti-inflammatory drugs and paracetamol).
preoperative window study of metformin for the treatment of endometrial cancer

Conditions: Endometrial Cancer

Summary: the overall goal of this proposal is to investigate the potential benefit of metformin as a novel therapy for the treatment of endometrial cancer. investigators will evaluate the effect of short-term metformin treatment on the endometrium of obese women with endometrial cancer by comparing each patient's endometrial biopsy before treatment with metformin to their post-treatment hysterectomy specimen. participants: obese women who are to undergo surgical staging for endometrial cancer will also receive short-term treatment (1-4 weeks) with metformin that will continue until the day prior to surgical staging. the effect of metformin on proliferation, apoptosis and downstream signaling pathways will be compared between pre-treatment endometrial biopsies and post-treatment hysterectomy specimens. tissue microarrays will be constructed and immunohistochemstry performed to evaluate proliferation, apoptosis and changes in critical signaling pathways mediated by metformin, and these findings will be correlated with our in vitro preclinical studies. fresh tissue will also be obtained, and western immunoblotting will be used to assess expression of the phosphorylated forms of the downstream targets of metformin. the hypothesis is that treatment with metformin will result in a decrease in proliferative markers and an increase in markers of apoptosis in the endometrial cancer tumors. ampk phosphorylation and inhibition of critical downstream targets of the mtor pathway will be seen in the post-treatment hysterectomy specimens. metabolomic profiling will also be performed of tumors and associated biofluids (i.e. serum and urine) before and after treatment with metformin to identify potential biomarkers of response to this therapy.


Eligibility criteria:
inclusion criteria: * be between the ages of 18-75 years old * have a confirmed diagnosis of type i endometrial cancer (endometrioid) based on pre-operative endometrial biopsy or dilation and curettage (d\&c) * be obese (bmi greater than or equal to 30) with or without diabetes * have no contraindications to short-term metformin therapy * have a serum creatinine greater 1.0 mg/dl * have normal serum transaminase values (ast and alt) * need to be able to undergo metformin treatment for a minimum of 1 weeks but no more than a maximum of 4 weeks prior to surgical staging exclusion criteria: * are currently taking metformin or have taken metformin in the past 6 months or have a history of an allergic reaction or intolerance at any time to metformin * have a history of liver or renal dysfunction * have a history of alcoholism * have a history of vitamin b12 deficiency * are pregnant * are currently taking insulin * are currently taking any hormonal therapy or have been on hormonal therapy in the past 4 weeks * are taking a drug that may significantly interact or influence the metabolism of metformin * in the opinion of the investigator, the patient is felt not to be appropriate for the study
a study of acthar gel alone or with tacrolimus to reduce proteinuria in fibrillary glomerulopathy patients

Conditions: Fibrillary Glomerulonephritis

Summary: a multicenter, comparative safety and efficacy study of acthar gel alone or in combination with oral tacrolimus to reduce urinary proteinuria in patients with idiopathic dnajb9 positive fibrillary glomerulopathy.

a multicenter, comparative safety and efficacy study of acthar gel alone or in combination with oral tacrolimus to reduce urinary proteinuria in patients with idiopathic dnajb9 positive fibrillary glomerulopathy. this study will be a multi-center, prospective, randomized, open-labeled intervention trial of 34 patients randomized to 52 weeks of acthar gel alone or acthar gel plus oral tacrolimus.

Eligibility criteria:
inclusion criteria: * male/female age \> 18 * biopsy proven fibrillary glomerulonephritis within 3 years of study randomization * stable maximum renin-angiotensin-aldosterone system inhibition times 4 weeks prior to randomization note: maximum raas inhibition will be left to the discretion of the site principal investigator * estimated glomerular filtration rate \> 25 mls/min calculate by the chronic kidney disease-epi formula * protein/creatinine ratio \> 2000 mg/gm 5) note: if protein/creatinine less than 2000 mg/gm, a formal 24- hour urine collection for total protein can be performed. the total 24-hour protein will need to \>/= 2000mg. * blood pressure targeted to \< 140/90 at the time of randomization * patients with monoclonal gammopathy without history of myeloma will be eligible. * patients with monoclonal staining for fibrillary fibers will be excluded * patients with type ii non-insulin dependent diabetes will be eligible provided the renal biopsy does not show nodular kimmelstiel wilson lesions exclusion criteria: * patients with mgus and history of myeloma will not be eligible * patients with active viral production of either hepatitis b or c as evidence by historical polymerase chain reaction test positive for active viral shedding * hiv seropositivity * renal biopsy data with \> 50% interstitial fibrosis * patient with active or a known history lymphoma * patients with insulin dependent diabetes mellitus will be excluded note: patients with type ii diabetes mellitus that are well controlled without the need for insulin will be eligible for the study. * patients with type ii non-insulin dependent diabetes will be eligible provided the renal biopsy does not show nodular kimmelstiel wilson lesions. * patients receiving steroids, mycophenolate mofetil, cyclophosphamide, azathioprine or other immunosuppressive agent with 4 weeks of study randomization note: washout of these medications will be allowed at the screening visit * patients having received rituximab or b cell modifying biologic therapy within 6 months of randomization
morphology of the vmo in patients with pfps and healthy young adults--a sonographic study

Conditions: Patellofemoral Pain Syndrome

Summary: background：patellofemoral pain syndrome（pfps） is a common knee disorder characterized by anterior or retropatellar pain associated with activities that load the patellofemoral joint. previous studies reveal that the vastus medialis obliquus（vmo） is an important dynamic medial stabilizer of the patellar. insufficiency of the vmo leads to lateral shift of the patella and the increases the patellofemoral contact force. an in vitro study conducted by hubbard jk. et al. claimed that there were no significant relationship between several morphologic characteristics of the vmo and the extent of patellofemoral joint deterioration. we consider that the condition might be different in vivo, so we chose ultrasonogrphy as the measurement tool to examine the morphology of the vmo in pfps patients and healthy controls. purpose：to determine if there are significant differences in several morphologic parameters of the vmo between patients with pfps and healthy controls under 50. method：31 pfps patients and 31 matched healthy adults under 50 were recruited for the study. the hdi 5000 ultrasonography machine was used to evaluate morphologic parameters of the vmo, including the percent of patella attachment, fiber angle, the volume attached to the patella, and the change of shape of the vmo.


Eligibility criteria:
inclusion criteria: 1. under 50 years old. 2. have a diagnosis of pfps. exclusion criteria: 1. diagnosis other than pfps，such as meniscal lesion, ligamentous instability ,patellar tendon pathology, traction apophysitis, radiation pain, referred pain, ect. 2. knee operation within three month. 3. x-ray findings (1)joint space narrowing (2)osteophyte formation
olive oil's cream effectiveness in prevention of pressure ulcers in immobilized patients in primary care

Conditions: Pressure Ulcer

Summary: pressure ulcers (upp) represent an important sanitary problem affecting mostly elderly immobilized persons, increasing the burden of care to professionals in the health system, as well as pharmaceutical spending. there are studies of the effectiveness of various products in the prevention of the upp, most made in hospitals and using fundamentally composed based on oily hyperbecome oxygenated acids (agho). there do not exist studies realized specifically with cream of olive oil. aims: principal: to verify the efficiency of a new intervention of upp's prevention in immobilized patients consisting in the application of cream of olive oil. secondary: to evaluate the cost - efficiency of this new intervention opposite to agho's application. to value the degree of satisfaction of the patient and his keeper with regard to the use of cream of olive oil. methodology design: clinical test randomized with two parallel branches. area: population consultant of the health centers in the province of malaga. subjects of study: patients immobilized at the risk of developing upp. intervention: administration of cream of olive oil to the group of intervention and agho's administration to the group control. follow-up for one year. variables. principal variable: upp's appearance. secondary: demographic and clinical data, presence of technical supports, information of the caragiver and questionnaire of satisfaction. statistical analysis: test. exact of fischer. odds's calculation ratio. shapiro-wilk's test. parametric test t- student or test u of mann-whitney. reason of the increase cost efficiency (icer). logistic regression model multivariant.


Eligibility criteria:
inclusion criteria: * patients with nursing diagnosis "risk of impaired skin integrity. "to determine this risk assessment tool we will use as the braden scale. we will include only patients immobilized with increased risk of pressure ulcers (score less than or equal to 16). * patients with malnutrition or suspected malnutrition. to determine this state as an instrument we will use mini nutritional assessment scale "mna" (score 10 points or less) * over 18 years. exclusion criteria: * patients refusal to participate in the study. * moved (patient no habitual residence in the health center where they make the study). * patients with plans to be out of the study area during the monitoring year. * hospitalized during the uptake phase of the sample * patient-terminal. * patient with the presence of pressure ulcers.

Keywords: pressure ulcer primary prevention fatty acids vegetable fats olive oil "pressure ulcer[prevention and control]"[mesh]
an open-label study to assess the pharmacokinetics and safety of halaven in subjects with cancer who also have impaired renal function

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Summary: this is an open-label non-randomized study in subjects with advanced or metastatic solid tumors who are no longer responding to available therapy. halaven will be administered to subjects on days 1 and 8 of a 21-day cycle.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed advanced solid tumors that have progressed following standard therapy or for which no standard therapy exists (including surgery or radiation therapy). * renal function must fall into one of the following categories: * normal function - creatinine clearance greater than or equal to 80 ml/min. * moderate impairment - creatinine clearance \>30 to 50 ml/min. * severe impairment - creatinine clearance 15 to less than 30 ml/min. * adequate liver function as evidenced by bilirubin less than or equal to 1.5 times the upper limit of normal (uln) and alkaline phosphatase (alp), alanine aminotransferase (alt), and aspartate aminotransferase (ast) less than or equal to 3 times the uln (in the case of liver metastasis less than or equal to 5 times uln). in the case alp \>3 times the uln (in the absence of liver metastasis) or \>5 times the uln (in the presence of liver metastasis), and the subject is also known to have bone metastasis, the liver specific alp must be separated from the total and used to assess the liver function instead of the total alp. exclusion criteria: * subjects with mild renal impairment (creatinine clearance greater than 50 to less than 80 ml/min). * subjects with end stage renal disease (creatinine clearance less than 15 ml/min or on dialysis). * subjects with a hypersensitivity to halichondrin b and/or halichondrin b chemical derivatives. * subjects with prior participation in an halaven clinical study, even if not previously assigned to halaven treatment. * radiation therapy encompassing \>30 % of bone marrow. * subjects with organ allografts requiring immunosuppression.

Keywords: unspecified advance solid tumor, protocol specific
optimal albuterol regimens for acute asthma exacerbations: dbrct pilot study

Conditions: Acute Asthma

Summary: our overall objective is to model a pediatric acute asthma clinical decision rule (adr) for personalized medicine by identification of treatment-response phenotypes that are important determinants of outcome. the specific aim of this study is to determine the feasibility of this approach by enrolling a pilot cohort of 16 participants in this dbrct of 4 different albuterol treatment regimens, 2 of which will use 10mg/hr and 2 of which will use 25mg/hr. within these dosages there will be a pulsed-treatment regimen and a continuous regimen.

the objective of this study is to determine the feasibility of this approach by enrolling a pilot cohort of 16 participants in this dbrct of 4 different albuterol treatment regimens, 2 of which will use 10mg/hr and 2 of which will use 25mg/hr. participants are randomized in randomly permuted blocks of four. within these dosages there will be a pulsed-treatment regimen and a continuous regimen.

Eligibility criteria:
inclusion criteria: * doctor diagnosed asthma * acute asthma exacerbation * treatment with systemic corticosteroids and nebulized albuterol * ages 5 to 17 years exclusion criteria: * other acute or chronic lung disease

Keywords: asthma acute asthma pediatrics
molecular analysis of thrombocytopenia and cancer (matac): investigating antigenic mimicry between platelets and tumor cells in patients with immune thrombocytopenia (itp) associated with cancer

Conditions: Immune Thrombocytopenia; Immune Thrombocytopenic Purpura; Neoplasms; Cancer

Summary: the association between hematologic malignancies and itp is well described, but this link is much less clear with solid cancers. in cases of itp associated with cancers, specific cancer treatment can lead to remission or even cure of itp. thus, our hypothesis was that chronic expression of gpiib by tumor cells could have initiated an autoimmune loop against gpiib, leading to the onset and perpetuation of itp.

autoimmune thrombocytopenia, also known as immune thrombocytopenic purpura (itp), is a rare autoimmune disease characterized by platelet destruction and impaired production, posing a life-threatening risk due to bleeding complications. the pathophysiology of itp involves complex mechanisms, including both defective platelet production and auto-reactivity of b and t lymphocytes leading to the production of autoantibodies against platelets, found in 35 to 55% of cases. additionally, in the context of neoplasia, some patients may develop varying degrees of thrombocytopenia, exacerbating morbidity and mortality. a multicenter, retrospective study will collect data from routine care, including birth date, gender, biological parameters related to itp, dates of treatment initiation and diagnosis of itp and cancer, types of treatments, and outcomes such as survival or death, without additional medical interventions or appointments.

Eligibility criteria:
inclusion criteria: * adult patients with a definite diagnosis of both itp and cancer; * synchronous diagnosis of itp and cancer; * onset of itp occurring 6 months before or after the diagnosis of cancer. exclusion criteria: * none

Keywords: proteomics mortality side effects multicenter retrospective
effect of phaseolus vulgaris l. dry extract on the modulation of weight and metabolic parameters

Conditions: Weight Loss

Summary: evaluation of the efficacy of phaseolus vulgaris l. dry extract on weight modulation.

monocentric, prospective, randomized, single-blind clinical trial to evaluate the effects of phaseolus vulgaris l. dry extract (test) on weight reduction and on metabolic parameters after 12 weeks of supplementation. the efficacy on weight reduction will be evaluated in comparison with the placebo group (control).

Eligibility criteria:
inclusion criteria: * male subjects aged between 18 and 60 years * bmi between 25 and 35 kg/m2 * habitual consumption of three main meals a day * stable body weight during the 3 months prior to enrollment * commitment to adhere to the diet and avoid the use of other weight loss products during the study * commitment not to change lifestyle significantly for the entire duration of the study. * signing of informed consent exclusion criteria: * hypergonadotropic hypogonadism and hypogonadotropic hypogonadism * diabetes mellitus * smoking \> 10 cigarettes/day * alcohol \> 2 alcohol units/day (equal to 24 g of ethanol) * history of eating disorders during the 12 months prior to enrollment * use of any drug or product to treat obesity (e.g. meal replacements) * presence of acute or chronic gastrointestinal diseases * active use of drugs that could influence the functions: gastrointestinal (e.g. laxatives, etc.), insulin (insulin sensitizers, etc.) and/or testicular (hormones, substances that influece testosterone production * known sensitivity to the ingredients of the preparation * any other clinical condition judged by the investigator to be incompatible with participation in the trial
the influence of antibiotics on the incidence of biliary tract infections after ptcd for malignant obstructive jaundice

Conditions: The Influence of Antibiotics on the Incidence of Biliary Tract Infections After PTCD for Malignant Obstructive Jaundice

Summary: to investigate the influence of antibiotics on the incidence of biliary tract infections after ptcd for malignant obstructive jaundice.

this project designed a large-scale, single-center, prospective randomized controlled clinical trial to explore the impact of antibiotics on the incidence of biliary tract infections after ptcd with malignant obstructive jaundice. this study will provide evidence-based medical evidence for the need for routine use of antibiotics to prevent biliary tract infections after ptcd with malignant obstructive jaundice, and provide references for clinicians to prevent patients from ptcd infections.

Eligibility criteria:
inclusion criteria: 1. 18-80 years old; 2. ecog score 0-1 before operation; 3. patients diagnosed as pancreatic head cancer and periampullary cancer according to preoperative imaging, including ampullary cancer, extrahepatic bile duct cancer and duodenal papillary cancer; 4. bilirubin\>200 mmol/l before ptcd , and the duration of ptcd continuous drainage \>2 weeks; 5. volunteer to participate and sign the informed consent form; exclusion criteria: 1. decompensated liver cirrhosis, acute and chronic hepatitis and other diseases before surgery; 2. a history of other malignant tumors before surgery; 3. duration of preoperative ptcd drainage\<2 weeks; 4. jaundice caused by other reasons besides cancer around the ampulla and cancer of the head of the pancreas;